WBC
CLDX icon

Westpac Banking Corp’s Celldex Therapeutics CLDX Stock Holding History

Westpac Banking Corp’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,156
Closed -$317K – 940
2014
Q4 		$317K Buy
+1,156
New +$287K ﹤0.01% 835

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westpac Banking Corp's CLDX Position: Q1 2015 in Review

Westpac Banking Corp sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 1,156 shares — an estimated $317K sold.

Westpac Banking Corp first reported a position in CLDX in Q4 2014 and held it in 1 quarter. The position peaked at $317K in Q4 2014. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

  • Westpac Banking Corp reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Westpac Banking Corp sold 1,156 Celldex Therapeutics shares in Q1 2015, an estimated $317K.
  • Westpac Banking Corp first reported a position in Celldex Therapeutics in Q4 2014 and held it in 1 quarter.
  • Westpac Banking Corp's Celldex Therapeutics position peaked at $317K in Q4 2014.
  • 193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on Westpac Banking Corp's 13F filing for Q1 2015, filed 12 May 2015.